Gain Therapeutics Reports CFO Resignation; CEO Named Interim CFO

What Happened
Gain Therapeutics, Inc. (GANX) filed an 8‑K reporting that Senior Vice President of Finance and principal financial and accounting officer Gianluca Fuggetta notified the company on September 22, 2026 that he will resign effective September 30, 2026. On September 24, 2026 the board appointed President and Chief Executive Officer Gene Mack to serve as interim Chief Financial Officer effective October 1, 2026. Mr. Mack will keep his roles as President and CEO while assuming the duties of principal financial officer and principal accounting officer until a permanent replacement is named.

Key Details

• Resignation: Gianluca Fuggetta to resign as SVP of Finance, principal financial officer and principal accounting officer, effective September 30, 2026.
• Interim appointment: Gene Mack (current President & CEO) appointed interim CFO effective October 1, 2026.
• Succession: Company is actively searching for a permanent replacement; Mr. Mack will serve until a successor is appointed or he is removed/resigns.
• Other disclosures: Mr. Mack’s compensation and other material employment terms remain unchanged; no family relationships or reportable related‑party transactions under Item 404(a) were identified.

Why It Matters
A change in the company’s principal financial officer is material because the CFO oversees financial reporting and controls. Investors should note the short gap between the resignation and the interim appointment and that the CEO is assuming CFO duties temporarily, which can affect management bandwidth and oversight. The company’s search for a permanent CFO is ongoing; watch for future filings announcing a hire or additional details about interim arrangements.